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ABSTRACT
Objective: Development and evaluation of selegiline-loaded bio-nanosuspensions using biopolymer which was isolated from seeds of Buchanania 
lanzan (Chironji), used as biostabilizer and compared with standard polymer.
Methods: The selegiline-loaded bio-nanosuspensions were prepared using novel biopolymer and standard stabilizer (hydroxypropyl methylcellulose) 
by sonication solvent evaporation method with different ratios (1%, 2%, 3%, 4%, and 5%) and evaluated for particle size, polydispersity index, zeta 
potential, pH stability studies, percentage entrapment efficacy, in vitro drug release, and stability studies.
Results: The prepared selegiline bio-nanosuspensions were subjected to the best formulation based on comparison of above-mentioned evaluation 
parameters, so Fb2 (2%) formulation was found to be the best formulation showing an R2=0.9842, T50% of 32 h and T80% of 70 h, respectively. 
According to the release kinetics, the best fit model was found to be Peppas-Korsmeyer with Fickian diffusion (Higuchi matrix) as the mechanism of 
drug release, and Fs5 (5%) formulation was found to be the best formulation showing an R2=0.9564, T50% of 25 h and T80% of 60 h, respectively. 
According to the release kinetics, the best fit model was found to be Peppas-Korsmeyer with Fickian diffusion (Higuchi matrix) as the mechanism 
of drug release. The biopolymer provided excellent stability for the formulation and resulting particle size for the best formulation was found to be 
360 nm. The best formulation was found to be polydispersity index of 0.43 with zeta potential of −5.12 mV.
Conclusion: The prepared bio-nanosuspensions using biopolymer were found to be safe and compatible with the novel drug delivery for the treatment 
of depression in comparison of standard polymer.
Keywords: Depression, Selegiline, Buchanania lanzan (Chironji), Biostabilizer, Bio-nanosuspension, Hydroxypropyl methylcellulose.
INTRODUCTION
Natural polysaccharides are recently getting consideration as 
biopolymers as they are economical, easily available, non-toxic, 
readily modified, biodegradable, and biocompatible. They find 
extensive applications in pharmaceutical and food industry due to 
their diversity in structure and properties [1]. The biopolymer which 
is used in this research work was isolated from seeds of Buchanania 
lanzan (Chironji) family Anacardiaceae. The seeds of Chironji contain 
proteins, carbohydrates, fiber, vitamins (C, B1, and B2), amino acid, 
iron, maleic acid, cardanol, linoleic acid, niacin, calcium, and few water-
soluble extracts. B. lanzan has been reported to have anti-inflammatory, 
relaxant, stimulant, diuretic, antiseptic, and expectorant activities [2].
Selegiline is a monoamine oxidase inhibitor (MAOI), a class of 
antidepressant medications that are not currently used extensively 
due to dietary tyramine restrictions and potential drug-drug 
interactions [3,4]. Selegiline is a preferential MAO-B inhibitor that is 
currently used as an adjunct therapy to treat late-stage Parkinson’s 
disease (PD). In addition, placebo-controlled clinical trials have shown 
it to have effective antidepressant activity. At therapeutic doses up to 
10 mg/day orally for PD, selegiline can be safely administered without 
the need for a tyramine-restricted diet. Oral selegiline may be an 
effective antidepressant [5,6] at doses in excess of 20 mg daily when 
enzyme selectivity is lost (MAO-A is inhibited in addition to MAO-B), 
thus necessitating tyramine dietary restrictions [7,8]. The selegiline 
bio-nanosuspensions differ from orally administered antidepressants, 
in that formulation can deliver sustained selegiline blood concentration 
sufficient to MAO-A and MAO-B in the brain, producing antidepressant 
effects, without substantially inhibiting MAO-A in the gastrointestinal 
tract, thereby reducing the risk of hypertensive crisis with the ingestion 
of tyramine-rich foods (i.e., “cheese effect”) [3,4].
Nanosuspension improves the dissolution rate, intestinal epithelium 
membrane permeability, and saturation solubility which makes it a 
choice for drug delivery system [9-15]. In recent decades, reducing 
drug particle size has been found to be able to increase drug dissolution 
rates. The dissolution rates of drugs can be expressed using the 
Noyes–Whitney equation. It is well known that reducing particle 
size increases total surface area, which subsequently increases the 
dissolution rate [16], Nanosuspension, refers to the reduction in drug 
particle size down to submicron range suitably stabilized by polymer 
and/or surfactants [17,18]. The mean size of these drug particles is in 
the nanometer range, typically between 10 and 1000 nm. Nanometer-
sized particles can increase drug solubility, the rate of dissolution, 
and mucosal adhesion. These factors are critical in improving the 
bioavailability of poorly soluble drugs and in determining their 
effectiveness and stability. Due to their nanometer-scale particle 
size and safe composition, nanosuspension can be delivered through 
various routes of administration such as the oral, ocular, and pulmonary 
pathways [19].
In the present research work, the biopolymer was isolated from seeds 
of B. lanzan (Chironji) and characterized by IR, differential scanning 
calorimetry, scanning electron microscopy analysis, and nuclear 
magnetic resonance (NMR) spectroscopy studies. The selegiline-
loaded bio-nanosuspensions were developed by novel method using 
biopolymer as a biostabilizer compared with standard stabilizer 
(hydroxypropyl methylcellulose [HPMC]). Further, formulations were 
comparatively evaluated for particle size, polydispersity index (PDI), 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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zeta potential, pH stability studies, percentage entrapment efficacy 
(%EE), in vitro drug release, and stability studies.
MATERIALS AND METHODS
Materials
Selegiline (assigned purity, 99.8%) was a gift from Lifecare Neuro 
Private Limited (Baddi, Himachal Pradesh, India). B. lanzan seeds were 
purchased from the market of Dehradun, Uttarakhand, India. All other 
chemicals and solvents were of analytical grade.
Isolation of biopolymer
100 g of the seeds of B. lanzan (Chironji) was procured from the market. 
The biopolymer was soaked in distilled water for overnight. The seeds 
were peeled off and slurry was prepared with 50 ml of distilled water 
with the help of grinder. The seeds were soaked in 100 ml of chloroform 
and kept for 1 h for removal of oil. Then, chloroform was removed 
through muslin cloth from the paste of seeds. Then, 200 ml of distilled 
water was added in the biopolymer for soaking and kept for 24 h in 
refrigerator for settling of sediment. The supernatant of biopolymer 
was taken and centrifuged at 3000 rpm for a period of 15 min. After 
centrifugation, the supernatant was taken and (1:2) 400 ml of acetone 
was added after optimization and kept for 24 h in refrigerator. Then, 
biopolymer was separated from acetone and dried in vacuum desiccator 
for 14 h. The dried biopolymer was purified by the hot dialysis method 
using an ORCHID scientific dialysis apparatus for complete removal of 
impurities such as chlorides and sulfates. The procedure was optimized 
by repeating 6 times and the percentage yield was calculated. The 
purified biopolymer was screened through 200# mesh and stored for 
later use [20].
Characterization of biopolymer
The isolated biopolymer was subjected to IR, differential scanning 
calorimetry (DSC), scanning electron microscopy (SEM) analysis, and 
NMR spectroscopy studies.
Preparation of bio-nanosuspensions
The selegiline-loaded bio-nanosuspensions were prepared using 
novel biopolymer isolated from B. lanzan (Chironji) as biostabilizer by 
sonication solvent evaporation method. Nanosized biopolymer (1%, 
2%, 3%, 4%, and 5%) was taken in glass mortar with nanosized drug 
(10 mg), 1% of dextrose and 0.9% sodium chloride (isotonic agent), 
and 0.1% of polyvinyl alcohol as a lubricant and antiaggregant, and the 
mixture was triturated properly for 2 min. After that, 10 ml of distilled 
water was added and mixture was triturated in uniform direction. 
The resulting solution was kept on magnetic stirrer for 30 min and 
then subjected for sonication at 10 cycles for 30 min (3 min of each 
cycle) to prepared bio-nanosuspension. Similarly, various formulations 
with different ratios were prepared by varying concentration of the 
biopolymer and HPMC as a standard polymer (Table 1) [21] .
Characterization of drug-loaded bio-nanosuspensions
The bio-nanosuspensions were evaluated for particle size, PDI, zeta 
potential, pH stability studies, %EE, in vitro drug release, and stability 
studies.
Particle size distribution and PDI
The average particle size and zeta potential values of the nanosuspension 
batches were measured using a Malvern Zetasizer Nano ZS90 (Malvern 
instruments) which were carried out at 25°C using plain folded 
capillary zeta cells. The diluted samples were placed directly into the 
cuvette and the data were collected for 10 times. All experiments were 
performed in triplicates and the average value was used from the each 
set of data [22].
Determination of zeta potential
PDI values were measured to understand the size distribution of 
the nanoparticles and the value range between 0.000 and 1.000, 
which demonstrates narrow to very wide size distribution of the 
particles[22].
pH stability studies
The pH values were measured at 25°C using a pH digital meter 
at 20±1°C. The formulation was brought in contact with the 
electrode of pH meter and equilibrated for 1 min. This method was 
done in triplicate and mean was calculated along with standard 
deviation [22].
%EE
The freshly prepared nanosuspension was centrifuged at 20,000 rpm 
for 20 min at 5°C temperature using cool ultracentrifuge. The amount 
of unincorporated drug was measured by taking the absorbance of the 
appropriately diluted 25 ml of supernatant solution at 268 nm using 
UV  spectrophotometer  against  blank/control  nanosuspensions.  Drug 
entrapment efficiency was calculated by subtracting the amount of 
free drug in the supernatant from the initial amount of drug taken. The 
experiment was performed in triplicate for each batch and the average 
was calculated [23]. The entrapment efficiency could be achieved by the 
following equation:
% Entrapment efficiency=Total drug-free drug×100÷Total drug
In vitro drug release studies
The in vitro drug diffusion assay was carried out in the M.S. diffusion 
apparatus. This was static method and requires complete replacement 
of the sample. Dialysis membrane was tied to the terminal portion of 
the cylindrical donor compartment. 2 ml of bio-nanosuspension was 
kept above the dialysis membrane in the donor compartment, and the 
receiver compartment was filled with diffusion medium. The complete 
sample was withdrawn at different time intervals and the receiver 
compartment was refilled with fresh medium. The amount of drug 
released was assessed by measuring the absorbance at 214 nm using 
UV spectrophotometer [20].
Stability studies
Stability of the selegiline nanosuspensions was investigated for 
6 months at ambient condition to monitor the change in appearance, 
physical characteristics, and release behavior. Two portions of selegiline 
nanosuspensions from same batch were kept under two different 
conditions (25°C, 60%RH and 40°C, 75%RH) [24].
Table 1: Formulation of selegiline bio-nanosuspensions using biopolymer and standard polymer with different concentrations
S. No. Formula Fb1 Fb2 Fb3 Fb4 Fb5 Fs1 Fs2 Fs3 Fs4 Fs5
1. Selegiline (mg) 10 10 10 10 10 10 10 10 10 10
2. Buchanania lanzan (biopolymer) (%) 1 2 3 4 5 - - - - -
3. HPMC (standard polymer) - - - - - 1% 2% 3% 4% 5%
4. Dextrose 5% 5% 5% 5% 5% 5% 5% 5% 5% 5%
5. PVA 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%
6. Sodium chloride 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9%
7. Benzalkonium chloride 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5%
8. Distilled water (mL) 10 10 10 10 10 10 10 10 10 10
PVA: Polyvinyl alcohol, HPMC: Hydroxypropyl methylcellulose
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Fig. 1: Infrared spectroscopy of biopolymer Buchanania lanzan
Fig. 2: Differential scanning calorimetry of biopolymer Buchanania lanzan
Fig. 3: Scanning electron microscopy of biopolymer Buchanania 
lanzan
RESULTS AND DISCUSSION
Isolation of the biopolymer
The biopolymer was isolated from by simplified economic process. The 
optimization of biopolymer isolation process was repeated 6 times 
for and the percentage yield was calculated. During optimization, the 
results obtained were reproducible with insignificant variation and 
can be adopted for scaling up in bulk manner. The percentage yield 
for biopolymer from seeds of B. lanzan was found to be of 10±4% w/w.
Characterization of biopolymer
IR spectroscopy
The result of the IR spectra of biopolymer isolated from seeds of B. lanzan 
displays a characteristic broad peak at 3236 cm−1 representing –OH 
hydroxyl group. Peaks at 1651 cm−1 and 1539 cm−1 can be attributed 
to C=C stretching of alkenes. Aliphatic C–O stretching was confirmed 
by the peak at 1097 cm−1. These functional groups are responsible for 
the stability of the biopolymer as these same groups are observed in 
polymer such as HPMC and Eudragit (Fig. 1).
DSC
The B. lanzan  showed  sharp  endothermic  transitions  at  ∼85°C. 
Biopolymer was shown to be the most effective stabilizers in all the 
characterization studies (Fig. 2).
SEM
The topology of biopolymer isolated from B. lanzan observed irregular, 
smooth,  granular  surface  topology  with  10  μm  in  size  at  1000 
magnifications. This clearly indicates that it is granular and polymeric 
in nature (Fig. 3).
NMR
The NMR spectra of biopolymer isolated from B. lanzan (Chironji) 
revealed that the peaks were found to be 25.22 ppm which showed the 
presence of methylene carbon atom CH3CO- group, 54.02 ppm which 
showed the presence of RCH2O group, 105.38 ppm which showed the 
presence of C-C group, and 172.89 ppm which showed the presence of 
C=C group. Hence, it clearly indicated that biopolymer was polymeric 
in nature (Fig. 4).
Characterization of drug-loaded bio-nanosuspensions
Particle size distribution and PDI of nanosuspensions using 
biopolymer
The particle size of selegiline was analyzed by Malvern Zetasizer. 
The z-particle size of bio-nanosuspension was found to be 360.8 nm. 
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The ability of nanoparticles to alter the biodistribution and 
pharmacokinetics of drug has important in vivo therapeutic application. 
Hence, the size and surface characteristics of nanoparticles are of 
prime important. Nanoparticles ranging 200 nm are easily captured 
by Kupffer cells or other phagocytic cell population that restrict 
biodistribution. These systems help in prolonging the duration of 
drug activity and increase the targeting efficiencies to specific site. 
Particle size distribution graph for formulation (Fb2) is shown in 
Fig. 5. PDI of 0.43 indicates narrowest size distribution. The PDI is 
the measure of size distribution of the nanoparticles, where it <0.5 
indicates monodisperse size distribution. These data also support the 
results observed using microscopic methods in the current study and 
suggest that nanosization was achieved for bio-nanosuspension.
Determination of zeta potential of nanosuspensions using 
biopolymer
The electric charge present on the bio-nanosuspension was evaluated 
by measuring the zeta potential as shown in Fig. 6. Zeta potential of 
Fig. 4: Nuclear magnetic resonance of biopolymer Buchanania lanzan
Fig. 5: Particle size and size distribution of bio-nanosuspension using biopolymer (Fb2)
Fig. 6: Zeta potential and size distribution of bio-nanosuspension using biopolymer (Fb2)
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Fig. 7: Particle size and size distribution of bio-nanosuspension using standard polymer (Fs5)
Fig. 8: Zeta potential and size distribution of bio-nanosuspension using standard polymer (Fs5)
formulation  (Fb2) was −5.18 mV which  indicates  significant  stability 
with no agglomeration. The value of particle surface charge indicates 
the stability of nanosuspensions at the macroscopic level. A minimum 
zeta  potential  of  ±30  mV  is  required  for  electrostatically  stabilized 
nanosuspensions  and  a minimum  of  ±20 mV  for  steric  stabilization. 
The zeta potential values are commonly calculated by determining 
the particle’s electrophoretic mobility and then converting the 
electrophoretic mobility to the zeta potential. Electroacoustic technique 
is also used for the determination of the zeta potential in the areas of 
material sciences.
Particle size distribution and PDI of nanosuspensions using 
standard polymer
The particle size of selegiline was analyzed by Malvern Zetasizer. The 
Z-particle size of bio-nanosuspension was found to be 610.4 nm. The 
ability of nanoparticles to alter the biodistribution and pharmacokinetics 
of drug has important in vivo therapeutic application. Hence, the size 
and surface characteristics of nanoparticles are of prime important. 
Nanoparticles ranging 200 nm are easily captured by Kupffer cells or 
other phagocytic cell population that restrict biodistribution. These 
systems help in prolonging the duration of drug activity and increase 
the targeting efficiencies to specific site. Particle size distribution graph 
for formulation (Fs5) is shown in Fig. 7. PDI of 0.40 indicates narrowest 
size distribution. The PDI is the measure of size distribution of the 
nanoparticles, where it <0.5 indicates monodisperse size distribution. 
These data also support the results observed using microscopic 
methods in the current study and suggest that nanosization was 
achieved for bio-nanosuspension.
Determination of zeta potential of nanosuspensions using 
standard polymer
The electric charge present on the bio-nanosuspension was evaluated 
by measuring the zeta potential as shown in Fig. 8. Zeta potential of 
formulation  (Fs5) was  −3.60 mV which  indicates  significant  stability 
with no agglomeration. The value of particle surface charge indicates 
the stability of nanosuspensions at the macroscopic level. A minimum 
zeta  potential  of  ±30  mV  is  required  for  electrostatically  stabilized 
nanosuspensions  and  a minimum  of  ±20 mV  for  steric  stabilization. 
The zeta potential values are commonly calculated by determining 
the particle’s electrophoretic mobility and then converting the 
electrophoretic mobility to the zeta potential. Electroacoustic technique 
is also used for the determination of the zeta potential in the areas of 
material sciences.
pH stability studies
The pH of the selegiline-loaded bio-nanosuspensions prepared using 
biopolymer (Fb1-Fb5) was found in the range of 7.3±0.2–7.5±0.2 
(Fig. 9) and pH of the selegiline-loaded bio-nanosuspensions prepared 
using standard polymer (Fs1-Fs5) was found in the range of 7.2±0.2–
7.5±0.2 (Fig. 10).
Fig. 9: pH stability studies of bio-nanosuspensions using 
biopolymer, mean of three observation ± standard  
deviation (n=3)
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%EE
The %EE of the selegiline-loaded bio-nanosuspensions prepared using 
biopolymer (Fb1-Fb5) was found in the range of 66±4–88±3% (Fig. 11) 
and %EE of the selegiline-loaded bio-nanosuspensions prepared using 
standard polymer (Fs1-Fs5) was found in the range of 63±2–79±4% 
(Fig. 12).
In vitro drug release studies
In vitro drug release studies were performed for all the formulations. 
The mechanism of selegiline released from the bio-nanosuspensions 
was studied by fitting the release data in different kinetic models 
such as zero order, first order, Higuchi matrix, Peppas-Korsmeyer, and 
Hixson Crowell and determining the R2 values of the release profile 
corresponding to each model. Its percentage drug release, T50%%, and 
T80%% were calculated and based on other parameters were arranged 
in decreased manner. The drug release pattern for formulations Fb1-
Fb5 containing biopolymer based on the T50% and T80% was found to 
be Fb2 (3%)>Fb4 (4%)>Fb1 (1%)>Fb3 (2%)>Fb5 (5%). In vitro drug 
release was performed for all the formulations and the data indicate 
that drug-loaded formulations show the sustained release behavior. 
Graph was plotted between percentage call detail record (CDR) and 
time, the R2 value, T50% and T80%, was calculated from graph, the 
FB2 (2%) formulation was found to be the best formulation showing 
an R2=0.9842, T50% of 32 h and T80% of 70 h, respectively. According 
to the release kinetics, the best fit model was found to be Peppas-
Korsmeyer with Fickian diffusion (Higuchi matrix) as the mechanism 
of drug release (Fig. 13). The drug release pattern for formulations Fs1-
Fs5 containing biopolymer based on the T50% and T80% was found 
to be Fs5 (5%)>Fs2 (2%)>Fs3(3%)>Fs4(4%)>Fs1 (1%). In vitro drug 
release was performed for all the formulations and the data indicate 
that drug-loaded formulations show the sustained release behavior. 
Fig. 11: Percentage entrapment efficacy of bio-nanosuspensions 
using biopolymer, mean of three observation ± standard 
deviation (n=3)
Fig. 12: Percentage entrapment efficacy of bio-nanosuspensions using standard polymer, mean of three observation ± standard  
deviation (n=3)
Fig. 10: pH stability studies of bio-nanosuspensions using 
standard polymer, mean of three observation ± standard 
deviation (n=3)
Table 2: Modeling and release kinetics of selegiline bio-nanosuspensions using biopolymer and standard polymer
Formulations Zero-order R2 First-order R2 Higuchi matrix R2 Korsmeyer-Peppas equation
R2 n
Fb1 0.7907 0.8743 0.9171 0.9790 0.5116
Fb2 0.8530 0.9493 0.9092 0.9842 0.4353
Fb3 0.7963 0.8700 0.9078 0.9699 0.4086
Fb4 0.7990 0.8757 0.9101 0.9786 0.4248
Fb5 0.8049 0.8897 0.9141 0.9693 0.4868
Fs1 0.7082 0.8137 0.9319 0.9308 0.5284
Fs2 0.7201 0.8233 0.9334 0.9458 0.5650
Fs3 0.7042 0.8123 0.9248 0.9443 0.4684
Fs4 0.6891 0.8103 0.9345 0.9412 0.5339
Fs5 0.6553 0.8010 0.9322 0. 9564 0.4947
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Fig. 13: In vitro drug release of bio-nanosuspensions using biopolymer Fb2, mean of three observation ± standard deviation (n=3)
Fig. 14: In vitro drug release of bio-nanosuspensions using standard polymer Fs5, mean of three observation ± standard deviation (n=3)
Graph was plotted between percentage CDR and time, the R2 value, 
T50% and T80%, was calculated from graph, the Fs5 (5%) formulation 
was found to be the best formulation showing an R2=0.9564, T50% of 
25 h and T80% of 60 h, respectively. According to the release kinetics, 
the best fit model was found to be Peppas-Korsmeyer with Fickian 
diffusion (Higuchi matrix) (Table 2) as the mechanism of drug release 
(Fig. 14).
Stability studies
At the end of stability study, the formulated bio-nanosuspensions 
showed little to no drug loss. The bio-nanosuspension also showed 
an insignificant difference for in vitro drug release. All optimized 
formulations showed satisfactory drug release and other properties 
during and at the end of the accelerated stability period. This indicates 
that there was no influence on the chemical and physical stability of the 
formulation during the test period.
CONCLUSION
The selegiline bio-nanosuspensions prepared by sonication solvent 
evaporation method. The biopolymer provided excellent stability for 
the formulation and resulting particle size, PDI, and zeta potential for 
the best formulation comparatively standard polymer. The prepared 
bio-nanosuspensions were found to be safe and compatible with 
the novel drug delivery for the treatment of depression, and this is a 
novelistic approach significantly delivering the drug for prolonged 
period, and the biopolymer was served as a promising excipient for 
delivering dosage forms.
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